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1. Introduction
  Osteoarthritis (OA) is a kind of degenerative joint 
diseases involved in all articular tissues, showing the 
chief manifestations such as articular cartilage disorders, 
conduction stress load abnormalities, and progressive 
cartilage degradation, eventually triggering cartilage 
thinning, fibrosis, erosions, fissures, ulcers and articular 
surface disappearance[1-4]. OA occurs predominantly in the 
middle-aged and the elderly, with high pain prevalence 
and high morbidity, which seriously affects their quality 
of life and brings about heavy burden to the society and 
family[5,6]. As the pathogenesis of OA remains unclear, the 
patients can not be radically cured. In addition, evidence 
suggests that metabolic imbalance between articular 
cartilage degradation and synthesis is the leading cause 
of OA cartilage degeneration. Matrix metalloproteinase 
family has attracted increasing attention as the promoter 
of cartilage extracellular matrix and basement membrane 
components degradation. Matrix metalloproteinase 3 (MMP3) 
is secreted from chondrocytes and synovial cells, it can 
not only degrade a variety of extracellular matrix, but also 
activate other protease serine[7-9]. It is known that MMP3 is 
expressed in OA synovium, however, there is little evidence 
available on the difference of MMP3 expression in synovial 
membrane at different stages of OA[10]. This study aims to 
verify the correlation between MMP3 and human OA and 
to explore the potential mechanism. We detected MMP3 
expression in the synovium of knee joint of OA patients at 
varying degrees with immunohistochemical method[11-13], 
in an effort to investigate the expression and significance of 
MMP3 in the pathogenesis of OA.
2. Materials and methods
2.1. Clinical data
  According to the diagnostic criteria formulated by 
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American Rheumatism Association[14], 90 OA patients were 
selected as the OA group. Then the involved patients were 
divided into three subgroups based on their lesions, which 
was assessed using the criteria of Kellgren and Lawrence: 
mild lesion group (n=30), moderate lesion group (n=30), 
and severe lesion group (n=30). There were 36 males and 
54 females, aged from 18 years to 81 years, with a mean of 
58.3 years. There were 30 non-OA patients in control group, 
including 14 cases with simple knee joint meniscus injury, 
9 cases with syndromatic synovial plica, and 7 amputated 
cases, aged 15-45 years, with a mean of 34.1 years.
  The synovial specimens were harvested following knee 
arthroscope, knee joint replacement or amputation between 
March 2012 and April 2013. The patients were informed 
of the sample harvesting and gave informed consent. The 
experimental proposal was approved by the Hospital Ethics 
Committee in China.
2.2. Main reagents
  The antibodies used for immunohistochemistry were rabbit 
anti-human polyclonal antibody (1:50; Abcam Company, 
Cambridge, USA) and horseradish peroxidase-conjugated 
goat anti-rabbit IgG (H+L; Beijing Zhongshan Golden Bridge 
Biotechnology Co., Ltd., Beijing, China). Envision kit was 
provided by Dako Company (Denmark).
2.3. Immunohistochemical staining
  All specimens were fixed in 10% formalin, embedded in 
paraffin, and sliced into serial sections in 4 毺m thickness. 
Immunohistochemical staining was performed according 
to the instructions of Envision kit, followed by antigen 
retrieval. TBS, instead of the first antibody, was used as 
blank controls.
2.4. Assessment criteria
  Immunohistochemical staining results were assessed with 
semi-quantitative integration method, namely the scores 
are graded according to the number of positive cells and the 
staining intensity of positive cells per slice, and then MMP3 
expression intensity was determined based on the sum 
of the above two scores. The staining intensity score was 
recorded as 0 point (no stains), 1 point (light yellow), 2 points 
(brown yellow), and 3 points (brown stains). The percentage 
of positive cells was the ratio of the number of positive 
cells to the total cell number. Each slice was observed in 
ten vision fields at 40 × 10 magnification and was classified 
according to the proportion of stained cells as follows: 0 
points, no staining or only < 10% cells stained; 1 point, 10%-
25% positive cells; 2 points, 25%-50% positive cells; 3 points, 
50%-70% positive cells; 4 point, 70%-100% positive cells. All 
slices were examined by two independent pathologists using 
a double-blind review method.
2.5. Statistical analysis
  Data were statistically analyzed using SPSS 17.0 software 
(SPSS, Chicago, IL, USA) and are expressed as mean依SD. 
Difference between groups was compared using analysis of 
variance and intragroup data were compared using t-test. 
The correlation analysis was performed using Pearson 
correlation analysis. A P < 0.05 was considered statistically 
significant difference.
3. Results
3.1. MMP3 expression in synovium 
  A small amount of light yellow-stained MMP3 were found 
in the cytoplasm of synovial tissue in the control group, 
and brown particles distributed in extracellular matrix 
(Figure 1A). MMP3 was mainly expressed in the cytoplasm 
of synovial tissue in the OA patient group, with a large 
number of brown particles; brown-yellow or brown particles 
were also visible in the cytoplasm, endothelial cells and 
inflammatory cells were apparently stained, synovial cells, 
vascular endothelial cells, monocytes and macrophages 
were strongly expressed in synovial lining layer and synovial 
sublining layer (Figures 1B-D). MMP-3 expression in OA 
groups (OA group: 2.09依0.16) were significantly higher than 
that in the control group (0.62依0.13), and it also showed 
significant differences in varying degree of OA: severe lesion 
group (3.02依0.19)> moderate lesion group (2.13依0.22)> mild 
lesion group (1.54依0.17).
A B
C D
Figure 1. MMP-3 expression.
A: control group (× 400); B: mild lesion group (× 400); C moderate 
lesion group (× 400); D severe lesion group (× 400).
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Correlation analysis showed that OA severity was positively 
correlated with MMP3 expression (r = 0.912, P < 0.05).
4. Discussion
  During the OA articular cartilage degeneration process, 
metabolic imbalance between degradation and synthesis of 
articular cartilage is the main reason for the degeneration. 
Among them, MMP functions to promote extracellular matrix 
and basement membrane components degradation[15,16]. MMP 
family are a class of zinc ion-dependent endopeptidases 
that are localized in a wide variety of connective tissue, it 
can degrade various extracellular matrix components such 
as collagen, proteoglycans, fibronectin and laminin[17-19].
  MMP3 is also known as stromelysin-1, MMP3 encoding 
gene is located on chromosome 11, MMP is secreted from 
chondrocytes and synovial cells as a 59/57 kDa zymogen 
that is proteolytically processed to the 45 and 28 kDa active 
forms. MMP can degrade the majority of collagens and 
matrix proteins such as proteoglycan and laminin, which 
contribute to damage articular cartilage. Importantly, it 
also activates other plasminogens and accordingly activates 
MMP1, MMP9, MMP13, thus producing “waterfall-like” 
amplification effect and facilitating the destruction of 
cartilage[20-24]. A previous study[25] showed that, MMP3 
levels in OA patient’s blood and synovial fluid were 
higher than that in healthy people, and the increment 
was consistent with the extent of cartilage damage; MMP3 
was highly expressed in OA synovium, suggesting that 
MMP3 expression in synovium is closely linked with the 
degradation of joint tissue in OA patients. The present 
study found that MMP-3 protein expression in synovial 
tissue of OA patient was significantly increased compared 
with control group, and the expression level was positively 
correlated with the severity of OA. This evidence indicated 
that MMP3 is progressively increasing as OA course and 
highlighted the contribution of MMP3 in OA pathogenesis. 
It is previously reported that, when MMP-3 is involved in 
OA cartilage damage process, synovial macrophages play 
a crucial role in the early MMP activity and induce MMP 
production in synovium, rather than in cartilage[26,27]. The 
aforementioned studies revealed that synovial changes 
in OA are not just the result of MMP3-mediated cartilage 
degradation; MMP-3 may play an independent important 
role in OA synovial tissue. Some scholars confirmed that 
miR-155 overexpression in RA synovial tissue could 
inhibit MMP3 expression[28]. Pap et al[29] found a positive 
correlation between MMP3 and uPA expression in cartilage 
tissue at different degrees of OA and they played a synergic 
role on promoting cartilage degradation, as detected by 
immunohistochemical staining. The above findings show 
that the abnormal intrinsic regulatory mechanisms in 
synovial tissue may stimulate MMP-3 secretion to various 
extents, activate other MMPs and produce amplification 
effect, thus generating many inflammatory cytokines 
such as interleukin-1. These inflammatory cytokines are 
secreted into the cartilage and can significantly increase 
MMP activity and content. When the increment exceeds 
the degree of increasing TIMPs, MMPs/TIMPs will loss the 
balance and degrade cartilage matrix type 栺, 栻, gelatin and 
fibronectin[13], thus promoting the degradation of articular 
cartilage matrix and inducing OA. Through a predetermined 
way, interleukin-1 and other inflammatory cytokines inhibit 
the expression of transcription factor, which is essential for 
cartilage regeneration, ultimately inhibit cartilage synthesis 
and restoration, and further deteriorate the destruction of 
articular cartilage[30,31]. MMP3’s function in synovium and 
cartilage allows to accelerate OA.
  The present study showed that MMP3 expression in OA 
patients had significant differences compared with control 
group, and MMP-3 levels was positively correlated with OA 
severity. This evidence suggests that MMP-3 play a potential 
crucial role in OA pathogenesis and development, and 
MMP-3 inhibitors can delay OA or remove synovial lesions 
by arthroscopic surgery. This can not only relieve pain and 
improve function, but also reduce inflammation factors 
production and slow down OA, so that patients will avoid 
premature artificial joint replacement and the resulting high 
cost. In addition, MMP-3 is considered an indicator of early 
diagnosis and disease activity of OA patients.
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